Stock SGBCF SHANGHAI HENLIUS BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Shanghai Henlius Biotech, Inc. Share Price OTC Markets

Equities

SGBCF

CNE100003N76

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Shanghai Henlius Biotech, Inc. -.--% -.--%
14/05 Shanghai Henlius Biotech Gets Go-Ahead for Clinical Trials of Breast Cancer Drug in China MT
14/05 Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 5.87B 814M 67.95B Sales 2025 * 6.45B 894M 74.61B Capitalization 8.85B 1.23B 102B
Net income 2024 * 594M 82.29M 6.87B Net income 2025 * 710M 98.36M 8.21B EV / Sales 2024 * 1.51 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 1.37 x
P/E ratio 2024 *
14.8 x
P/E ratio 2025 *
12.3 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 15.03%
More Fundamentals * Assessed data

Chart Shanghai Henlius Biotech, Inc.

Dynamic Chart

Latest news about Shanghai Henlius Biotech, Inc.

Shanghai Henlius Biotech Gets Go-Ahead for Clinical Trials of Breast Cancer Drug in China MT
Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration CI
Henlius Biotech Gets US FDA Clearance for Phase 3 Trial of Gastric Cancer Combination Therapy MT
Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration CI
Henlius Biotech Logs 1.35 Billion Yuan Revenue in Q1 MT
Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA MT
Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China MT
Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China CI
Henlius Biotech Gets Clearance for China Clinical Trial of Carcinoma Drug MT
Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of HLX53 (Anti-TIGIT Fc Fusion Protein) in Combination with HANSIZHUANG (Serplulimab Injection) and HANBEITAI (Bevacizumab Injection) for the First-Line Treatment of Local Advanced or Metastatic Hepatocellular Carcinoma was Approved by the National Medical Products Administration CI
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint MT
Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® Biosimilar Candidate HLX14 Met Primary Endpoints CI
Phase 3 Trial of Shanghai Henlius Biotech’s Osteoporosis Drug Meets Primary Study Endpoints MT
Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints CI
Shanghai Henlius Biotech Turns to Profit in 2023 MT
More news

Press releases Shanghai Henlius Biotech, Inc.

Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated) AQ
Henlius maintained a positive momentum of development in Q1 2024, with impressive performances by core products AQ
Shanghai Henlius Biotech, Inc. - IND Application for the Clinical Trial of Novel Anti-TIGIT Fc Fusion Protein HLX53 in Combination with HANSIZHUANG Plus HANBEITAI Approved by NMPA AQ
Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity PR
Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development PR
More press releases

Managers and Directors - Shanghai Henlius Biotech, Inc.

Managers TitleAgeSince
Wei Dong Jiang FOU
 Founder - 01/09/01
Jun Zhu CEO
 Chief Executive Officer 46 30/21/30
Wei Huang PSD
 President 56 01/20/01
Members of the board TitleAgeSince
Qi Yu Chen BRD
 Director/Board Member 52 15/13/15
Tak Young So BRD
 Director/Board Member 54 02/19/02
Xiao Hui Guan BRD
 Director/Board Member 53 24/18/24
More insiders

Quotes

Date Price Change
14/24/14 - +-NaN%
13/24/13 - -100.00%

Delayed Quote OTC Markets, January 01, 1970 at 05:30 am IST

More quotes

Company Profile

Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
Sector
Pharmaceuticals
Calendar
20/05/2024 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Ratings for Shanghai Henlius Biotech, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
16.28 CNY
Average target price
16.7 CNY
Spread / Average Target
+2.62%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
+0.10% 91.42B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 41.08B
BIOGEN INC. Stock Biogen Inc.
-9.06% 34.26B
UCB Stock UCB
+53.99% 25.27B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.61% 15.27B
INCYTE CORPORATION Stock Incyte Corporation
-9.14% 12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.11% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.61% 11.42B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+3.60% 9.16B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 2696 Stock
  4. SGBCF Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW